Literature DB >> 26785615

Cryptogenetic liver cirrhosis and prothrombotic mutations - A mere association?

María Monereo Muñoz1, Selena Gala Aguilera García1, Raquel de la Barreda Heusser2, Emilio González Arnay3, Sonia García Hernández4, Emilio González Reimers5.   

Abstract

Thrombin activation and microthrombosis of intrahepatic portal venules is a common feature in liver cirrhosis, due in part to relative protein C deficiency and altered coagulation-anticoagulation-fibrinolysis balance. Extension of this microthrombotic process to larger portal vessels explains the increased incidence of portal vein thrombosis in liver cirrhosis. Thrombin not only leads to thrombosis, but also activates liver stellate cells and promotes fibrogenesis. Also, ischemia associated with thrombosis up-regulates the expression and secretion of growth factors involved in fibrogenesis. The coincidence in a given patient of prothrombotic mutations, such as factor V Leiden or PAI-1 polymorphisms, can accelerate the fibrogenetic process. We hereby present two cases of liver cirrhosis in which etiologic evaluation was negative except for the finding of a factor V Leiden mutation in one case and the 4G/5G PAI polymorphism in the second case. These observations support the hypothesis that these mutations may be involved in the etiology of some cases of cirrhosis, or, at least, accelerate the evolution of the disease. It is therefore convenient to search for the presence of prothrombotic mutations in patients with cryptogenetic cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26785615     DOI: 10.17235/reed.2016.3871/2015

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  1 in total

1.  Population Pharmacokinetics and Dosage Optimization of Linezolid in Patients with Liver Dysfunction.

Authors:  Su-Hua Zhang; Zhen-Yu Zhu; Zi Chen; Ying Li; Yang Zou; Miao Yan; Yun Xu; Feng Wang; Mou-Ze Liu; Min Zhang; Bi-Kui Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.